Compare Omnicom Group Inc. (OMC) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Oruka Therapeutics Inc. Common Stock — how do they compare? Omnicom Group Inc. trades at $78.65 (market cap $21.53B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Omnicom Group Inc. is far larger — about 4.2× Oruka Therapeutics Inc. Common Stock's market cap, and Omnicom Group Inc. pays a 4.08% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 64 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| OMC | ORKA | |
|---|---|---|
Market Cap | $21.53B | $5.18B |
Volume | 2,515,610 | 490,798 |
Sector | Media | Health |
52-Week High | $88.94 | $113.08 |
52-Week Low | $67.27 | $26.19 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | $29.61B | $4.31B |
Dividend Yield | 4.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $78.41, up 1.74% with a bullish technical signal despite mixed earnings results. The company shows strong revenue growth to $17.27B in 2025 but reported a net loss of -$54.50M. Analyst consensus is mixed with 32% buy ratings and a $100.50 price target, while recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings.
OMC presents a value opportunity with attractive P/S of 0.88 and dividend yield, though high P/E of 212.14 reflects earnings volatility. Key risks include advertising market weakness and elevated debt levels, while AI capabilities and post-Interpublic synergies offer growth catalysts for patient investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
